valine has been researched along with valganciclovir in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zaia, JA | 1 |
| Emery, VC; Leśnikowski, ZJ; Olejniczak, A; Paradowska, E; Przepiórkiewicz, M | 1 |
| Guex-Crosier, Y; Meylan, PR | 1 |
| Brandl, M; Stefanidis, D | 1 |
| Falagas, ME; Vardakas, KZ | 1 |
| Hes, O; Jindra, P; Klaboch, J; Reischig, T; Svecová, M; Treska, V | 1 |
| Amidon, GL; Lai, L; Lee, KD; Xu, Z; Zhou, J | 1 |
| Smolej, L | 1 |
| Bowlin, TL; Drach, JC; Prichard, MN; Wu, Z; Yanachkov, I; Yanachkova, M; Zemlicka, J | 1 |
| Bouda, M; Hes, O; Jindra, P; Nemcová, J; Reischig, T; Treska, V; Vanecek, T | 1 |
| Akl, A; Blancho, G; Cantarovich, D; Dantal, J; Giral, M; Leone, F; Soulillou, JP | 1 |
| Aydinli, B; Bilen, Y; Cetinkaya, R; Keles, M; Polat, KY; Turkmen, M; Uyanik, A; Yildirim, R | 1 |
| Chiang, CC; Lin, TH; Tien, PT; Tsai, YY | 1 |
| Khuroo, A; Mishra, S; Monif, T; Saxena, S; Singh, O | 1 |
| Razonable, RR | 1 |
| Reischig, T | 1 |
| Bouda, M; Jindra, P; Lysak, D; Matejovic, M; Prucha, M; Reischig, T; Sedlackova, L | 1 |
| Brennan, DC; Santos, RD | 1 |
| Bouda, M; Hes, O; Hribova, P; Jindra, P; Reischig, T; Treska, V; Viklicky, O | 1 |
| Alexopoulos, SP; Lindberg, L; Matsuoka, L; Subramanyan, RK | 1 |
| Cunningham, ET; Fu, A; Johnson, RN; Jumper, JM; Lujan, BJ; McDonald, HR; Wong, RW | 1 |
| Beersma, MF; Bouts, AH; Cornelissen, EA; Cransberg, K; Jongsma, H | 1 |
| Bouda, M; Hes, O; Jindra, P; Kacer, M; Lysak, D; Reischig, T | 1 |
| Bouda, M; Kacer, M; Kielberger, L; Reischig, T | 1 |
4 review(s) available for valine and valganciclovir
| Article | Year |
|---|---|
[Drugs against human cytomegalovirus].
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drugs, Investigational; Female; Foscarnet; Ganciclovir; Global Health; Humans; Infectious Disease Transmission, Vertical; Naphthalenesulfonates; Organophosphonates; Organophosphorus Compounds; Pregnancy; Pregnancy Complications, Infectious; Thionucleotides; Valacyclovir; Valganciclovir; Valine | 2002 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
Topics: Acyclovir; Antiviral Agents; Clinical Protocols; Cytomegalovirus Infections; Ganciclovir; Humans; Immunosuppressive Agents; Opportunistic Infections; Organ Transplantation; Randomized Controlled Trials as Topic; Valacyclovir; Valganciclovir; Valine | 2012 |
Emerging concepts in the management of acute retinal necrosis.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cytomegalovirus Retinitis; Eye Infections, Viral; Famciclovir; Fluorescein Angiography; Ganciclovir; Herpes Simplex; Humans; Laser Coagulation; Retinal Necrosis Syndrome, Acute; Valacyclovir; Valganciclovir; Valine | 2013 |
5 trial(s) available for valine and valganciclovir
| Article | Year |
|---|---|
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Topics: Acyclovir; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Czech Republic; Ganciclovir; Humans; Incidence; Kidney Transplantation; Middle Aged; Prospective Studies; Valacyclovir; Valganciclovir; Valine | 2008 |
Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Double-Blind Method; Ganciclovir; Graft Rejection; Humans; Kidney Transplantation; Postoperative Complications; Premedication; Risk Factors; Transplantation, Homologous; Treatment Outcome; Valacyclovir; Valganciclovir; Valine; Viremia | 2010 |
Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection.
Topics: Acyclovir; Calibration; Chromatography, Liquid; Drug Stability; Ganciclovir; Humans; Reproducibility of Results; Tandem Mass Spectrometry; Time Factors; Valacyclovir; Valganciclovir; Valine | 2011 |
Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Topics: Acyclovir; Adult; Antiviral Agents; Atrophy; Biopsy; Cytomegalovirus; Cytomegalovirus Infections; Female; Fibrosis; Follow-Up Studies; Ganciclovir; Graft Survival; Humans; Kaplan-Meier Estimate; Kidney; Kidney Transplantation; Longitudinal Studies; Male; Middle Aged; Treatment Outcome; Valacyclovir; Valganciclovir; Valine | 2012 |
Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Topics: Acute Disease; Acyclovir; Adult; Antiviral Agents; Biomarkers; Biopsy; Cytomegalovirus; Cytomegalovirus Infections; Czech Republic; DNA, Viral; Drug Administration Schedule; Female; Ganciclovir; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kidney Transplantation; Male; Middle Aged; Time Factors; Treatment Outcome; Valacyclovir; Valganciclovir; Valine; Viral Load | 2015 |
15 other study(ies) available for valine and valganciclovir
| Article | Year |
|---|---|
Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Organophosphonates; Organophosphorus Compounds; Postoperative Complications; Risk Factors; Transplantation, Autologous; Transplantation, Homologous; Valacyclovir; Valganciclovir; Valine | 2002 |
High dosage of oral valaciclovir as an alternative treatment of varicella zoster acute retinal necrosis syndrome.
Topics: Acyclovir; Antiviral Agents; Eye Infections, Viral; Ganciclovir; Herpes Zoster; Humans; Retinal Necrosis Syndrome, Acute; Valacyclovir; Valganciclovir; Valine | 2006 |
Reactivity of valganciclovir in aqueous solution.
Topics: Buffers; Chromatography, High Pressure Liquid; Ganciclovir; Half-Life; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Solutions; Stereoisomerism; Valganciclovir; Valine | 2005 |
Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Ganciclovir; Humans; Organ Transplantation; Valacyclovir; Valganciclovir; Valine | 2006 |
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase.
Topics: Acyclovir; Animals; Antiviral Agents; Binding Sites; Carboxylic Ester Hydrolases; Crystallography, X-Ray; Ganciclovir; Humans; Hydrophobic and Hydrophilic Interactions; Mutation; Phylogeny; Prodrugs; Protein Structure, Tertiary; Valacyclovir; Valganciclovir; Valine | 2008 |
Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
Topics: Acyclovir; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus Infections; Ganciclovir; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Valacyclovir; Valganciclovir; Valine | 2008 |
L-valine ester of cyclopropavir: a new antiviral prodrug.
Topics: Animals; Antiviral Agents; Biological Availability; Cyclopropanes; Cytomegalovirus; Esters; Ganciclovir; Guanine; Humans; Hydrolysis; Mice; Prodrugs; Valganciclovir; Valine; Virus Replication | 2009 |
Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Female; Follow-Up Studies; Ganciclovir; Graft Survival; Humans; Incidence; Injections, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Prodrugs; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Valacyclovir; Valganciclovir; Valine | 2010 |
Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Cytomegalovirus Infections; Filgrastim; Ganciclovir; Granulocyte Colony-Stimulating Factor; Humans; Kidney Transplantation; Male; Neutropenia; Recombinant Proteins; Treatment Outcome; Valacyclovir; Valganciclovir; Valine | 2010 |
Atypical presentation of cytomegalovirus endotheliitis: a case report.
Topics: Acyclovir; Aged; Antiviral Agents; Corneal Edema; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Endothelium, Corneal; Ganciclovir; Humans; Intraocular Pressure; Keratitis, Herpetic; Male; Prednisolone; Valacyclovir; Valganciclovir; Valine; Visual Acuity | 2011 |
Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
Topics: Acyclovir; Adult; Antiviral Agents; Cell Proliferation; Cells, Cultured; Concanavalin A; Cytomegalovirus; Cytomegalovirus Infections; Female; Ganciclovir; Graft Rejection; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Phytohemagglutinins; T-Lymphocyte Subsets; Valacyclovir; Valganciclovir; Valine | 2011 |
Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Ganciclovir; Humans; Kidney Transplantation; Male; Valacyclovir; Valganciclovir; Valine | 2012 |
Cytomegalovirus prophylaxis in solid organ transplantation.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Graft Rejection; Humans; Immunity, Cellular; Immunosuppressive Agents; Risk Factors; Tissue Transplantation; Valacyclovir; Valganciclovir; Valine | 2012 |
Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
Topics: Acyclovir; Adolescent; Antiviral Agents; Child; Child, Preschool; Cytomegalovirus; Cytomegalovirus Infections; Disease-Free Survival; Ganciclovir; Humans; Immunoglobulins; Immunosuppressive Agents; Infant; Kidney Transplantation; Netherlands; Polymerase Chain Reaction; Receptors, Interleukin-2; Renal Insufficiency; Retrospective Studies; Risk; Valacyclovir; Valganciclovir; Valine | 2013 |
Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
Topics: Acyclovir; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Ganciclovir; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Valacyclovir; Valganciclovir; Valine | 2015 |